换一批Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS.
第一作者：
Amy E,DeZern
第一单位：
Johns Hopkins University, Hematologic Malignancies, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.
作者：
Amy E,DeZern [1]
;
Sylvain,Thepot [2]
;
Stephane,de Botton [3]
;
Andrea,Patriarca [4]
;
Dries,Deeren [5]
;
Jose-Miguel,Torregrossa-Diaz [6]
;
Giovanni,Marconi [7]
;
Teresa,Bernal [8]
;
Juan,Bergua Burgues [9]
;
Blanca,Xicoy [10]
;
Anna,Jonášová [11]
;
Amer M,Zeidan [12]
;
Sophie,Dimicoli-Salazar [13]
;
Célestine,Simand [14]
;
David,Valcarcel [15]
;
Maria,Diez Campelo [16]
;
Wanxing,Chai-Ho [17]
;
Lalit,Saini [18]
;
Alice,Garnier [19]
;
Klaus,Geissler [20]
;
Yishai,Ofran [21]
;
Zsolt,Nagy [22]
;
Pramila,Krishnamurthy [23]
;
Michael,Lübbert [24]
;
Grzegorz,Basak [25]
;
Hetty E,Carraway [26]
;
David A,Sallman [27]
;
Uma,Borate [28]
;
Valeria,Santini [29]
;
Victoria,Campbell [30]
;
Pierre,Fenaux [31]
;
Thorsten,Braun [32]
;
Francesco,Lanza [33]
;
Jan Maciej,Zaucha [34]
;
David A,Roth [35]
;
Sofia,Paul [35]
;
Pourab,Roy [35]
;
Michael J,Kelly [35]
;
Angela,Volkert [35]
;
Jaime,Chisholm [35]
;
Tanya Abdul,Malak [35]
;
Virginia M,Klimek [35]
;
Thomas,Cluzeau [36]
作者单位：
Johns Hopkins University, Hematologic Malignancies, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.
[1]
Centre Hospitalier Universitaire, Hematology, Angers, France.
[2]
Institut Gustave Roussy, Department of Hematology, Villejuif, France.
[3]
Hematology Unit, AOU Maggiore della Carità and University of Eastern Piedmont, Novara, Italy.
[4]
AZ Delta, Department of Hematology, Roeselare, Belgium.
[5]
Centre Hospitalier Universitaire de Poitiers, University Hospital of Poitiers, Department of Hematology, Poitiers, France.
[6]
Romagnolo Institute to Study Tumors "Dino Amadori," Department of Hematology, Meldola, Italy.
[7]
Hospital Universitario Central de Asturias, Department of Hematology, Oviedo, Spain.
[8]
Hospital San Pedro de Alcántara, Department of Hematology, Caceres, Spain.
[9]
Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Deparment of Leukemia Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.
[10]
Medical Department Hematology, Charles University General Hospital, Prague, Czech Republic.
[11]
Yale University and Yale Cancer Center, Division of Hematologic Maignancies, New Haven, CT.
[12]
Hôpital Haut-Lévêque, Centre Hospitalier Universitaire de Bordeaux, Hematology, Bordeaux, France.
[13]
Institut de Cancérologie de Strasbourg Europe, Hematology, Strasbourg, France.
[14]
Hospital Universitario Vall d'Hebron, Department of Hematology, Barcelona, Spain.
[15]
Hospital Universitario de Salamanca, Institute of Biomedical Research of Salamanca, Salamanca, Spain.
[16]
Division of Hematology and Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA.
[17]
Division of Hematology, Department of Medicine, London Health Sciences Centre, London, ON, Canada.
[18]
Hematology Clinic, Nantes University Hospital, Nantes, France.
[19]
Hospital Hietzing, Vienna, Austria.
[20]
Department of Hematology, Shaarei Zedek Medical Center, Jerusalem, Israel.
[21]
Department of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary.
[22]
Department of Haematological Medicine, King's College Hospital, London, United Kingdom.
[23]
University of Freiburg Medical Center, Freiburg, Germany.
[24]
Medical University of Warsaw, Warsaw, Poland.
[25]
Leukemia Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
[26]
Moffitt Cancer Center and Research Institute, Department of Malignant Hematology, Tampa, FL.
[27]
Leukemia and Hematologic Malignancies Program, The Ohio State University, Columbus, OH.
[28]
MDS Unit, Department of Medical Sciences and Public Health, AOU Careggi, University of Florence, Firenze, Italy.
[29]
Lothian Health Board Western General Hospital in National Health Service Lothian, Edinburgh, Scotland.
[30]
Département d'Hématologie et Immunologie, Assistance Publique-Hôpitaux de Paris Nord Service d'Hématologie Seniors Hôpital St Louis/Université de Paris, Paris, France.
[31]
Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris Service Hématologie, Paris, France.
[32]
Ospedale Santa Maria delle Croci, Hematology, Ravenna, Italy.
[33]
Department of Haematology and Transplantology, Medical University of Gdańsk University Clinical Center, Gdańsk, Poland.
[34]
Syros Pharmaceuticals, Inc, Cambridge, MA.
[35]
Centre Hospitalier Universitaire de Nice, Nice, France.
[36]
医学主题词
人类(Humans);阿扎胞苷(Azacitidine);男(雄)性(Male);骨髓增生异常综合征(Myelodysplastic Syndromes);女(雌)性(Female);中年人(Middle Aged);老年人(Aged);成年人(Adult);苯甲酸盐类(Benzoates);四氢萘类(Tetrahydronaphthalenes);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);治疗结果(Treatment Outcome);老年人, 80以上(Aged, 80 and over)
DOI
10.1182/bloodadvances.2025016229
PMID
40334070
发布时间
2025-09-15
- 浏览0
Blood advances
Blood advances
2025年9卷16期
4090-4099页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
